secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entera Bio Ltd. (ENTXW)
CIK:        0001638097
Form:       8-K
Filed at:   2022-03-08T23:59:59+00:00
Accession:  0001178913-22-000990
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entera Bio reports $12.2M net loss for 2021; guides FY2022 operating loss of $25-30M; EB613 Phase 3 trial in 2022
--------------------------------------------------------------------------------

- Revenue $571k in 2021 vs $365k in 2020; net loss $12.2M ($0.47 per share) vs $11.2M ($0.67 per share).
- Cash $24.9M at Dec 31, 2021; $21.7M at Mar 1, 2022; expects FY2022 operating loss $25-30M.
- EB613 (osteoporosis) Phase 3 pivotal trial expected to start in 2022 after positive FDA End of Phase 2 meeting.
- EB612 (hypoparathyroidism) improved formulation; next clinical trial planned in 2022; Orphan Drug status FDA and EMA.
- Engaged Torreya Capital as financial advisor for non-dilutive strategic alliances for EB613.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638097/000117891322000990/0001178913-22-000990-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638097/000117891322000990/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001178913-22-000990

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer